



IGG and IGM response in a group of Iraqi health care worker following SARS-CoV-2 mRNA vaccine

Amar Kasim Muhamad¹, Russell A. Abo-Altamen²

¹Baghdad teaching hospital Medical city compound, Assistant Professor and Consultant in Medicine and Respiratory medicine.

²Al Hikma College, medical laboratory technique

***Corresponding author:** Amar Kasim Muhamad, Baghdad teaching hospital Medical city compound, Assistant Professor and Consultant in Medicine and Respiratory medicine,
Email: amaralfahd@ymail.com

Submitted: 14 February 2023; Accepted: 08 March 2023; Published: 04 April 2023

ABSTRACT

The global pandemic of coronavirus disease 2019 (COVID-19) is caused by infection with the SARS-CoV-2 virus. Positive detection of IgM and IgG antibodies specific to SARS-CoV-2 has been recognized as an evidence for confirmed SARS-CoV-2 infection or vaccination.

Method: One hundred healthy health care workers from both genders over eighteen years old were participated to test their humeral response (IgG, IgM) after vaccinated with Pfizer vaccine in the vaccination center Baghdad Teaching Hospital after one week of the second shot, and one hundred healthy health care workers with matched age and gender had test of their humeral response (IgG, IgM) before they get vaccinated (control), both groups deny recent COVID-19 infection.

Result: Our finding shows that increase antibody responses of both (IgG, IgM) following vaccination with lesser extent increase of IgM titer than the obvious increase IgG titer in our entire participant compared with control.

Conclusion our result support that the vaccine successful in production of humoral immunity and protection against COVID-19 infection.

Keywords: COVID-19, IgG, IgM.

INTRODUCTION

Severe acute respiratory syndrome (SARS) virus disease represent a major threat to public health. Epidemiological investigations have suggested that the outbreak was associated with a seafood market in Wuhan China in 2019[1, 2] more than 680 million people were infected worldwide, including more than 6.8 million related deaths (<https://covid19.who.int/>). Successful vaccination strategies have already provided

significant protection against at least 31 human diseases [3], and it's one of the powerful measures to prevent and block the transmission of communicable diseases[4]. 4,814 million people were vaccinated worldwide with Covid-19 vaccines (<https://covid19.who.int/>). Positive detection of SARS-CoV-2 RNA in nasopharyngeal swab samples, sputum samples or bronchoalveolar lavage samples

by reverse transcriptase polymerase chain reaction (RT-PCR) has been used to confirm SARS-CoV-2 infection[5] Humoral immune responses play critical roles in protecting individuals against SARS-CoV-2 infection, particularly through the production of neutralizing antibodies. Understanding humeral immune reactions to SARS-CoV-2 and how these reactions impact vaccine-induced immunity is needed specially immunoglobulin M (IgM), IgG.[6, 7] Although SARS-CoV-2 infection has been more carefully investigated using IgG and IgM antibody responses, there have been limited studies contributed to response of IgG and IgM antibody after vaccination, US Food and Drug Administration (FDA)-approved SARS-CoV-2 vaccines that are based on messenger RNA (mRNA) [8, 9] it has been demonstrated that after a single dose of SARS-CoV-2 mRNA vaccine, individuals with previous infection have more robust antibody responses when compared to infection-naive individuals [10, 11,12,13] This boost of preexisting antibody immunity from prior infection may be considered when deciding whether a single or double dose is required for vaccine-mediated protection in individuals with prior history of infection.

We aim to provide an estimate of antibody responses for both genders in three different age groups between vaccinated and non-vaccinated after one week to second dose of SARS-CoV-2 vaccination of Pfizer.

MATERIAL AND METHODS

Individuals and sample collection

We enrolled two groups, first group one hundred healthy health care workers from both genders over eighteen years old one week after vaccinated with the second Pfizer covid-19 vaccine in the vaccination center Baghdad Teaching Hospital, who had no known history of infection. Peripheral blood was collected from 50 male and 50 female from December 1/ 2021 to March 1/2022, and another group , one hundred healthy health care workers with matched age and gender had test of their humeral response (IgG, IgM) before they get vaccinated (control) .

This study was approved by the latter hospital in Baghdad governorate. Before the survey, participants were asked verbal consent to identify their willingness to take part in this study, and to ensure their rights of voluntary participation and privacy.

IgG and IgM antibody assay

To measure antibody levels of IgG and IgM titer we utilized Fluorescence Immunoassay (FIA) covid-19 titer technology following standard manufacture protocols considering <0.04 Negative and > 0.04 Positive for both IgG and IgM antibody levels with control using BIOT-YG-I FIA Immunoassay Analyzer.

Statistical analysis

All statistical analysis was performed with SPSS version 25.0 software (IBM SPSS) and a P-value <0.05 was considered to be statistically significant.

RESULTS

As of December 1/ 2021 to March 1/2022, the vaccination center of the medical city in Baghdad has vaccinated more than 100 individuals with Pfizer vaccine (50 male & 50 female) . We measured immunoglobulin G (IgG) and immunoglobulin M (IgM) antibody levels after one week of the second shot. IgG and IgM below 0.04 are considered as a negative response and values higher than 0.04 are considered positive response for both genders in all age group. Mean of IgG level for male were 6.98 and 0.027 for IgM in vaccinated cases, while the mean of IgG for female were 5.360 and 0.032 for IgM in vaccinated cases. At the same time Mean of IgG for male were 0.028 and 0.022 for IgM in control (non-vaccinated) cases and mean of IgG for female were 0.028 and 0.022 for IgM in control (non-vaccinated) cases. P- Value for IgG and IgM considered statistically significant for vaccinated and non-vaccinated (control) in both genders as shown in table 1, figure 1 & 2

TABLE 1: P-Value for IgG and IgM for vaccinated and non-vaccinated (control) in both male and female

Sex	Test	Control	±	Se	Vaccinated	±	Se	P-Value	Significant P ≤ 0.05
		Mean	±	Se	Mean	±	Se		Significant P ≤ 0.05
Male	Igg	0.028	±	0.001	6.980	±	0.213	0.000	S
Female	Igg	0.028	±	0.001	5.360	±	0.278	0.000	S
Male	IgM	0.022	±	0.001	0.027	±	0.003	0.039	S
Female	IgM	0.022	±	0.001	0.032	±	0.006	0.041	S




FIG 1: IgG titer in both genders for all age groups




FIG 2: IgM titer in both genders for all age groups

DISCUSSION

To the best of our knowledge, this is the first study on the association of vaccinations and immunoglobulin G (IgG) and immunoglobulin M (IgM) antibody for male and female in Iraq. IgG considered antibodies specific for covid-19 spike protein following vaccination and used to estimate vaccine response in Iraq, while IgM antibodies estimate immunity to SARS –cov-2 [14] Similar to other respiratory infections, SARS-CoV-2 infection stimulates rapid production of IgM, IgG antibodies, which are measurable in the sera, including those that bind to nucleocapsid and the spike protein [15,16,17,18,19,20]. In the post-vaccination era, IgM responses and those against nucleoprotein were much less prevalent [21] we have noticed IgM antibodies titer showed a low secondary response that was different from the IgG [22] In responses were associated with higher IgG antibodies titers [23] Jo-Lewis Banga Ndzouboukou et al., [24] found IgG antibody levels were significantly higher than IgM levels ($P < 0.0001$). Sex had no effect on IgM and IgG antibody response after the second dose, which supports our result. Jassim et al., [25] found significant variations in immunoglobulin (IgG) levels ($P \leq 0.05$) between case (Recipients mRNA vaccination) and control patients, there were. In terms of age and gender, however, there were no significant changes ($P \geq 0.05$) in immunoglobulin (IgM) levels between case (Recipients mRNA vaccination) and control patients, which also support our finding.

CONCLUSIONS

Our finding shows that increase antibody responses of both (IgG, IgM) following vaccination with lesser extent increase of IgM titer than the obvious increase IgG titer in all our participant compared with control , which support that the vaccine successful in production of humoral immunity.

CONFLICT OF INTEREST

The Authors declare that they have no conflict of interests.

REFERENCES

1. Drosten, C., et al., Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *New England journal of medicine*, 2003. 348(20): p. 1967-1976.
2. Wolfe, N.D., C.P. Dunavan, and J. Diamond, Origins of major human infectious diseases. *Nature*, 2007. 447(7142): p. 279-283.
3. Stern, P.L., Key steps in vaccine development. *Annals of Allergy, Asthma & Immunology*, 2020. 125(1): p. 17-27.
4. Liu, A., et al., Antibody responses against SARS-CoV-2 in COVID-19 patients. *Journal of medical virology*, 2021. 93(1): p. 144.
5. Amanat, F., et al., A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nature medicine*, 2020. 26(7): p. 1033-1036.
6. Long, Q.-X., et al., Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature medicine*, 2020. 26(6): p. 845-848.
7. Feldstein, L.R., et al., Multisystem inflammatory syndrome in US children and adolescents. *New England Journal of Medicine*, 2020. 383(4): p. 334-346.
8. Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... & Gruber, W. C. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New England journal of medicine*, 383(27), 2603-2615.
9. Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., ... & Zaks, T. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *New England journal of medicine*, 384(5), 403-416.
10. Bradley, T., Grundberg, E., Selvarangan, R., LeMaster, C., Fraley, E., Banerjee, D., ... & Schuster, J. (2021). Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine. *New England Journal of Medicine*, 384(20), 1959-1961.
11. Krammer, F., Srivastava, K., Alshammari, H., Amoako, A. A., Awawda, M. H., Beach, K. F., ... & Simon, V. (2021). Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. *New England Journal of Medicine*, 384(14), 1372-1374.
12. Manisty, C., Otter, A. D., Treibel, T. A., McKnight, Á., Altmann, D. M., Brooks, T., ... & Moon, J. C. (2021). Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. *The Lancet*, 397(10279), 1057-1058.
13. Saadat, S., Tehrani, Z. R., Logue, J., Newman, M., Frieman, M. B., Harris, A. D., & Sajadi, M. M. (2021). Binding and neutralization antibody

- titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. *Jama*, 325(14), 1467-1469.
14. Ruggiero, A., Piubelli, C., Calciano, L., Accordini, S., Valenti, M. T., Dalle Carbonare, L., ... & Zipeto, D. (2022). SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals. *EBioMedicine*, 77, 103888.
 15. Long, Q. X., Liu, B. Z., Deng, H. J., Wu, G. C., Deng, K., Chen, Y. K., ... & Huang, A. L. (2020). Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature medicine*, 26(6), 845-848.
 16. Piccoli, L., Park, Y. J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., ... & Veesler, D. (2020). Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. *Cell*, 183(4), 1024-1042.
 17. Suthar, M. S., Zimmerman, M. G., Kauffman, R. C., Mantus, G., Linderman, S. L., Hudson, W. H., ... & Wrarmert, J. (2020). Rapid generation of neutralizing antibody responses in COVID-19 patients. *Cell Reports Medicine*, 1(3), 100040.
 18. Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut, R., Markmann, A. J., ... & de Silva, A. M. (2020). The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Science immunology*, 5(48), eabc8413.
 19. Isho, B., Abe, K. T., Zuo, M., Jamal, A. J., Rathod, B., Wang, J. H., ... & Gingras, A. C. (2020). Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Science immunology*, 5(52), eabe5511.
 20. Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J., ... & Doores, K. J. (2020). Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nature microbiology*, 5(12), 1598-1607.
 21. Karachaliou, M., Moncunill, G., Espinosa, A., Castaño-Vinyals, G., Rubio, R., Vidal, M., ... & Dobaño, C. (2022). SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia. *BMC medicine*, 20(1), 1-16.
 22. Xu, Q. Y., Xie, L., Zheng, X. Q., Liang, X. M., Jia, Z. J., Liu, Y. Y., ... & Lin, L. R. (2023). Anti-SARS-CoV-2 IgM Secondary Response Was Suppressed by Preexisting Immunity in Vaccinees: A Prospective, Longitudinal Cohort Study over 456 Days. *Vaccines*, 11(1), 188.
 23. Jalkanen, P., Kolehmainen, P., Häkkinen, H. K., Huttunen, M., Tähtinen, P. A., Lundberg, R., ... & Julkunen, I. (2021). COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. *Nature communications*, 12(1), 3991.
 24. Jo-Lewis Banga Ndzouboukou, Yan-di Zhang, Qing Lei, Xiao-song Lin, Zong-jie Yao, Hui Fu, Le-yong Yuan & Xiong-lin Fan, Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine, *Current Medical Science* volume 41, pages1081–1086 (2021).
 25. Jassim, F. K.; Kareem, A. K.; Khadairi, M. M.; Mera, N. A..., Study of IgG and IgM antibody response afterPfizer mRNA Vaccine first dose in Previously infected with COVID-19and uninfected individuals, *NeuroQuantology* ; 20(8):7591-7595, 2022.